Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tactiva Therapeutics

Request full access

Developing next generation adoptive cell therapy strategies that deliver lethal hits to cancer cells

Buffalo, United StatesFounded 2016Biotech & Life Sciences

About Tactiva Therapeutics

Tactiva Therapeutics is a pioneering immuno-oncology company focused on developing advanced cancer immunotherapies. Specializing in adoptive cell therapy (ACT), Tactiva employs a dual T cell receptor approach to reprogram patients' own T cells to recognize, attack, and destroy cancer cells. This strategy aims to provide a robust and sustained immune response against tumors. The company primarily serves patients battling various forms of cancer, operating within the biopharmaceutical market. Tactiva's business model revolves around the research, development, and clinical application of its proprietary immunotherapy technologies. Revenue is generated through clinical trials, partnerships, and potential future commercialization of its therapies. The company's leadership includes experienced professionals with extensive backgrounds in biopharma and academia, ensuring strong guidance and innovative research.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
56.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, Cancer Care Companion, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Dec 2018 $35M $140M Efung Capital · Panacea Venture · Viventures ↗
SEEDEquity / VC Jul 2016 $1.5M $6M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Tactiva Therapeutics website traffic

Latest recorded traffic for Tactiva Therapeutics is 980 monthly website visits, up 216.1% over the last three months. Tactiva Therapeutics's team grew 0% over the past year.

Latest monthly visits980 3-month web change+216.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tactiva Therapeutics in the Buffalo ecosystem

Live from Dealroom

The Tactiva Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Panacea Venture
  • Efung Capital
  • Viventures

Other known investors1 additional known investor

  • University of Buffalo
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tactiva Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tactiva Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.